Players: Thermo Fisher, Merck KGaA, Danaher, Agilent and QIAGEN. Profile covers CRISPR screening segments, trends, competition, regions and opportunities.Dublin, Oct. (GLOBE NEWSWIRE) -- "Pooled ...

Researchers generated eyeless F0 CRISPR-Cas9 pax6 mutants in the slipper limpet Crepidula fornicata using a de novo ...

CRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer and principal financial officer on October 19, 2026 ...

Scientists used CRISPR/Cas9 to disrupt the tyr and oca2 pigmentation genes in zebrafish, reducing melanophores and visibly ...

Spread the loveImagine looking in the mirror and seeing a younger version of yourself, not just cosmetically, but at a ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Spread the loveImagine turning back the clock, not on your watch, but on your very own cells. It sounds like something ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.39, moving -1.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.52%.

Kyverna Therapeutics advances Miv-cel for autoimmune diseases, but valuation, launch, and funding risks remain. Click here to ...

As of Wednesday, October 28, Scribe Therapeutics Inc.’s SCTX share price has surged by 5.08%, which has investors questioning ...

Organoids are full of cells that shouldn’t be there, and sorting them out wrecks the vasculature. SynBITE prunes in place instead.

March 25, 2020. A letter was issued by the Center for Food Safety and Applied Nutrition of the U.S. Food and Drug ...